Joinn Laboratories (06127) signed a partnership agreement to invest in the Beinao Phase I (Beijing) Equity Investment Center (Limited Partnership)

Joinn Laboratories (06127) announced that on December 20, 2024, the company held the eleventh meeting of the fourth board of directors, and approved the "Proposal on the Company's Cooperation with Professional Investment Institutions to Participate in Investment Funds", agreeing that the company or its designated subsidiaries can invest up to 8 million RMB to participate in the equity investment center of Beinao Phase I (Beijing) by North Brain Investment. Recently, the company's wholly-owned subsidiary Beijing Zhaoyan Management Technology Co., Ltd. signed a partnership agreement with Beijing Chongde Yingsheng Investment Management Co., Ltd. and other partners involved in this fund. The limited partnership focuses on brain science, mainly investing in medical equipment, consumables, and drugs used in the diagnosis and treatment of brain diseases in the field. The limited partnership gives priority to investing in early-stage small and medium-sized enterprises in the Changping area, with the total investment amount not less than 50% of the limited partnership's total investment amount.